BD meets the needs of pharmaceutical vaccine manufacturers, from conventional inactivated vaccines to cutting-edge mRNA technology
In contrast to prophylactic vaccines which prevent disease, therapeutic vaccines enhance the body’s response to an existing illness.
Therapeutic vaccines have the potential to treat a range of conditions, from infectious disease1 to cancer.2 Vaccine development is fast moving, and therapeutic vaccine research is exploring the treatment of a variety of conditions.
Cancers, such as HPV vaccine4, using proteins produced by cancer cells to stiumlate a strong immune response to existing tumors.3
Respiratory disease such as tuberculosis.1
Infectious disease such as Hepatitis B5 using antisense oligonucleotides (ASO) to target viral mRNA and decrease the level of viral proteins.5
New mRNA-based vaccines are both powerful and versatile and are hoped to be used as therapies for conditions that are currently untreatable6 including infectious diseases,6 cardiovascular disease,7 genetic disorders7 and cancer.8
To meet the demand for the rapid development of vaccines, pharmaceutical manufacturers must adopt innovative practices to ensure:
Flexiblity
Capacity
Regulatory compliance
Optimal processing
On-time delivery
With years of experience BD understands the specific challenges faced by the industry, including accommodating the delivery of mRNA vaccines.
The selection of a suitable drug container is important. Consideration must be given to:
Stability and potential degradation of vaccine components9
Mechanical performance and end-to-end container reliability10
Quality and safety
Regulatory scrutiny11
Continuity of supply12
Cost
Designed in consultation with pharma experts, BD glass prefilled syringes for vaccines are suitable for a wide range of molecules including some mRNA formulations and oligonucleotides:
Benefit from continuous development programs and high-volume production capacity
Support patient safety13
Chosen by the top 5 pharmaceutical companies14,15
Benefits of partnering with BD extend beyond high quality products and high production capacity.
Our experts will also support the development of your vaccine from early development to commercial manufacturing.
The BD Accuspray™ Nasal Spray System delivers accurate nasal drug
and vaccine administration, with demonstrated ease of use.16
BD Effivax™ Glass Prefillable Syringe for Vaccines
BD Accuspray™ Nasal Spray with BD Hypak™ Glass Prefillable Syringe technology for nasal drug delivery
BD Hypak™ for Vaccines Glass Prefillable Syringe
BD Uniject™ Auto-Disable Prefillable Injection System
BD Effivax™ Glass Prefillable Syringe for Vaccines
1. Bouzeyen R, Javid B. Therapeutic Vaccines for Tuberculosis: An Overview. Frontiers in Immunology. 2022;13:878471. Published 2022 Jun 24.
2. Edward Winstead. Can mRNA Vaccines Help Treat Cancer - National Cancer Institute-January 20, 2022
3. Liam Drew. How does a cancer vaccine work ? Nature 627, S34-S35 (2024). doi: https://doi.org/10.1038/ d41586-024-00841-y 27 March 2024
4. Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Frontiers in Immunology. 2020;11:188. Published 2020 Feb 18.
5. Yuen MF, Lim SG, Plesniak R, et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. November 8, 2022 N Engl J Med 2022;387:1957-1968 DOI: 10.1056/NEJMoa221002
6. Qin S, Tang X, Chen Y, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy 2022;7(1):166. Published 2022 May 21.
7. Kirkpatrick, P. Widening the horizons of oligonucleotide drug platforms. Nature. Dec 2023. B17-19 doi: https://doi.org/10.1038/d43747-023-00104-1
8. Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Molecular Cancer. 2021;20(1):41. Published 2021 Feb 25.
9. Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, Wu X, Xu M. Research Advances on the Stability of mRNA Vaccines. Viruses. 2023; 15(3):668. https://doi.org/10.3390/v15030668
10. BD Internal document. Market research, Voice of customer study, Genactis. 2018.
11. Sanduria S et al. 2020. Voicing regulatory perspectives of the combination products. J Generic Med. 2020;16(3):101-111
12. Fraiser Kansteiner. The next big COVID-19 bottleneck? A shortage of trained vaccine workers, experts say., Fierce Pharma, Apr 23 2021.
13. Moreira, ME. Et al. Color-Coded Prefilled Medication Syringes Decrease Time to Delivery and Dosing Error in Simulated Emergency Department Pediatric Resuscitations. Annals of Emergency Medicine pp. 97-106 2015
14. Market analysis and product sales for Vaccines, from 2014 to 2018 [internal analysis]. Pont de Claix, FR: Becton, Dickinson and Compagny; 2019
15. Vaccines Market Leaders, https://www.statista.com/statistics/314562/leading-global pharmaceuticalcompanies-byvaccine-revenue/ Accessed 4th April 2018
16. Dubé et al., April 2015, Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada, Human Vaccines & Immunotherapeutics. Survey conducted to explore knowledge, attitudes and practices of 314 vaccine providers regarding use of LAIV. During the vaccination campaign, 71% responded having used LAIV. Almost all of these respondents indicated that it was easy to vaccinate children with the vaccine (57% strongly agreed).
